目录产品 » Anti-Ranibizumab Antibody, pAb, Rabbit
Anti-Ranibizumab Antibody, PAb, Rabbit

ELISA binding of Anti-Ranibizumab Antibody, pAb, Rabbit (GenScript, A02037-40) with Ranibizumab.
Coating antigen: Ranibizumab, 1 µg/ml.
Anti-Ranibizumab Antibody, pAb, Rabbit (GenScript, A02037-40) dilution start from 1,000 ng/ml.
EC₅₀= 29.68 ng/ml.

Anti-Ranibizumab Antibody, pAb, Rabbit

The product is specific for Ranibizumab.
A02037
¥1980

联系我们
Specificity The product is specific for Ranibizumab.
Host Species Rabbit
Immunogen Ranibizumab
Conjugate Unconjugated

Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Application Recommended Usage
ELISA 0.05-1 µg/ml

Form Lyophilized
Storage Buffer Lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.
Reconstitution Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Storage Instructions The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
Purification Antigen affinity purification
Isotype Rabbit IgG
Clonality Polyclonal
Note GenScript can customize this product per customer's request including product size, buffer components, etc.

  • Anti-Ranibizumab Antibody, PAb, Rabbit
  • Anti-Ranibizumab Antibody, PAb, Rabbit

    ELISA binding of Anti-Ranibizumab Antibody, pAb, Rabbit (GenScript, A02037-40) with Ranibizumab.
    Coating antigen: Ranibizumab, 1 µg/ml.
    Anti-Ranibizumab Antibody, pAb, Rabbit (GenScript, A02037-40) dilution start from 1,000 ng/ml.
    EC₅₀= 29.68 ng/ml.


Target Background Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity. GenScript Anti-Ranibizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Ranibizumab.
Synonyms Mouse monoclonal to Lucentis

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


喜欢新升级的网站吗?

讨厌

不喜欢

一般

喜欢

非常喜欢

*